These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 7636538)

  • 1. Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.
    Rowinsky EK; Noe DA; Grochow LB; Sartorious SE; Bowling MK; Chen TL; Lubejko BG; Kaufmann SH; Donehower RC
    J Clin Oncol; 1995 Aug; 13(8):1975-84. PubMed ID: 7636538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
    Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
    J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients.
    Grem JL; Harold N; Keith B; Chen AP; Kao V; Takimoto CH; Hamilton JM; Pang J; Pace M; Jasser GB; Quinn MG; Monahan BP
    Clin Cancer Res; 2002 Jul; 8(7):2149-56. PubMed ID: 12114415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer.
    Pelley R; Ganapathi R; Wood L; Rybicki L; McLain D; Budd GT; Peereboom D; Olencki T; Bukowski RM
    Cancer Chemother Pharmacol; 2000; 46(3):251-4. PubMed ID: 11021744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
    LoRusso P; Foster BJ; Poplin E; McCormick J; Kraut M; Flaherty L; Heilbrun LK; Valdivieso M; Baker L
    Clin Cancer Res; 1995 Dec; 1(12):1487-93. PubMed ID: 9815948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer.
    Dees EC; Rowinsky EK; Noe DA; O'Reilly S; Adjei AA; Elza-Brown K; Donehower RC
    Invest New Drugs; 2003 Feb; 21(1):75-84. PubMed ID: 12795532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
    Plaxe SC; Blessing JA; Olt G; Husseinzadah N; Lentz SS; DeGeest K; Valea FA
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):151-4. PubMed ID: 12172981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial.
    Galanis E; Buckner JC; Maurer MJ; Reid JM; Kuffel MJ; Ames MM; Scheithauer BW; Hammack JE; Pipoly G; Kuross SA
    Invest New Drugs; 2005 Oct; 23(5):495-503. PubMed ID: 16133802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
    Rowinsky EK; Grochow LB; Hendricks CB; Ettinger DS; Forastiere AA; Hurowitz LA; McGuire WP; Sartorius SE; Lubejko BG; Kaufmann SH
    J Clin Oncol; 1992 Apr; 10(4):647-56. PubMed ID: 1312588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma.
    Zalupski MM; Philip PA; LoRusso P; Shields AF
    Cancer Chemother Pharmacol; 1997; 40(3):225-7. PubMed ID: 9219505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix--a Gynecologic Oncology Group Study.
    Plaxe SC; Blessing JA; Lucci JA; Hurteau JA
    Invest New Drugs; 2001; 19(1):77-80. PubMed ID: 11291835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer.
    Adjei AA; Reid JM; Erlichman C; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Ruben S; Boemer SA; Atherton P; Ames MM; Kaufmann SH
    Invest New Drugs; 2002 Aug; 20(3):297-304. PubMed ID: 12201492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study.
    Plaxe SC; Blessing JA; Bookman MA; Creasman WT
    Gynecol Oncol; 2002 Jan; 84(1):32-5. PubMed ID: 11748972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies.
    Villalona-Calero MA; Eder JP; Toppmeyer DL; Allen LF; Fram R; Velagapudi R; Myers M; Amato A; Kagen-Hallet K; Razvillas B; Kufe DW; Von Hoff DD; Rowinsky EK
    J Clin Oncol; 2001 Feb; 19(3):857-69. PubMed ID: 11157040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
    Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
    J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma.
    Zalupski MM; Shields AF; Philip PA; Kraut M; LoRusso P; Heilbrun LK; Vaitkevicius V
    Invest New Drugs; 1998; 16(1):93-6. PubMed ID: 9740550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
    Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
    J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study.
    Plaxe SC; Blessing JA; Morgan MA; Carlson J;
    Am J Clin Oncol; 2002 Feb; 25(1):45-7. PubMed ID: 11823695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
    O'Reilly S; Fleming GF; Barker SD; Walczak JR; Bookman MA; McGuire WP; Schilder RJ; Alvarez RD; Armstrong DK; Horowitz IR; Ozols RF; Rowinsky EK
    J Clin Oncol; 1997 Jan; 15(1):177-86. PubMed ID: 8996140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.